Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Non-Small Cell Carcinoma: early-phase trial registry
23 of 48 indexed Lung Non-Small Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #297 of 28,707 conditions by registered trial count.
48 US clinical trials · 23 currently recruiting · #297 of 28,707 conditions by registered trial count
Lung Non-Small Cell Carcinoma: 48 US clinical trials tracked, 23 recruiting.
Lung Non-Small Cell Carcinoma is the subject of 48 registered US clinical trials on ClinicalTrials.gov, 23 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition lung-non-small-cell-carcinoma
OPEN 23 | RECR 48% | LATE 5 | EARLY 26 | RANK #297 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Aging (48% recruiting · 263 trials)
Lung Non-Small Cell Carcinoma lists 23 open slots (48% of 48 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Non-Small Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Non-Small Cell Carcinoma is recruiting above its size-band peers.
23 of 48 indexed trials (47.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lung Non-Small Cell Carcinoma research.
M.D. Anderson Cancer Center accounts for 11 of 48 trials (22.9%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Lung Non-Small Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 47 among the 48 trials that report a genuine target (sentinel values excluded). 32 of those (66.7%) plan for fewer than 100 participants.
-
Lung Non-Small Cell Carcinoma research is mostly interventional.
40 interventional and 8 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
48 total, page 1 of 1
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Wake Forest University Health Sciences
NCT06418204
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
NCT04267848
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
M.D. Anderson Cancer Center
NCT03948100
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
NCT06498635
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
City of Hope Medical Center
NCT06139627
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04913311
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
Roswell Park Cancer Institute
NCT05292521
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
Thomas Jefferson University
NCT05502523
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
Mayo Clinic
NCT06122064
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
Fred Hutchinson Cancer Center
NCT06983899
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT06116682
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
Northwestern University
NCT05802186
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
Mayo Clinic
NCT06918132
Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD
University of Southern California
NCT07186699
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
University of Southern California
NCT07339254
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
City of Hope Medical Center
NCT06014827
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
NCT05830058
Gilteritinib for the Treatment of ALK NSCLC
University of Michigan Rogel Cancer Center
NCT06225427
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
NCT05672108
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
NCT05501665
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
Mayo Clinic
NCT06660407
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Emory University
NCT05493566
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Alan Davis
NCT07216404
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04214262
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
City of Hope Medical Center
NCT04428905
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03391869
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
NCT05106374
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
M.D. Anderson Cancer Center
NCT03410043
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT04625647
Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
NCT04946279
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
M.D. Anderson Cancer Center
NCT04430725
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Roswell Park Cancer Institute
NCT02955290
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT04073745
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
NCT04310020
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
M.D. Anderson Cancer Center
NCT04407247
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
NCT03634241
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
NCT02983578
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03707938
Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy
Ohio State University Comprehensive Cancer Center
NCT05717998
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03637816
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT03546361
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
M.D. Anderson Cancer Center
NCT04013542
Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases
Ohio State University Comprehensive Cancer Center
NCT03824327
Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT04032418
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
University of Washington
NCT05242965
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
University of Southern California
NCT05340309
Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer
Thomas Jefferson University
NCT03944265
Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer
Mayo Clinic
NCT05740501
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 16 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Non-Small Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Non-Small Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Non-Small Cell Carcinoma page
48 registered trials, 23 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 23 Lung Non-Small Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Lung Non-Small Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Non-Small Cell Carcinoma condition card totals 48 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.